Last reviewed · How we verify
Fluanxol (FLUPENTIXOL)
Flupentixol works by blocking the histamine H1 receptor, which helps regulate various physiological processes including mood and cognition.
Fluanxol (Flupentixol) is a small molecule high-risk QT prolonging agent that targets the histamine H1 receptor. It is used to treat schizophrenia, but its commercial status is unknown. The drug has a half-life of 34.2 hours and bioavailability of 50%. Key safety considerations include its potential to prolong the QT interval, a risk factor for serious cardiac arrhythmias. Its approval status and generic availability are also unclear.
At a glance
| Generic name | FLUPENTIXOL |
|---|---|
| Drug class | High Risk QT Prolonging Agents |
| Target | Histamine H1 receptor |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Mechanism of action
Think of histamine like a messenger in your brain that can make you feel anxious or excited. Flupentixol blocks this messenger, helping to calm down overactive brain signals that can contribute to schizophrenia symptoms. By reducing these signals, flupentixol can help improve mood and cognitive function.
Approved indications
- Schizophrenia
Common side effects
- Blood prolactin abnormal
- Anosognosia
- Disturbance in social behaviour
- Sexual dysfunction
- Metabolic disorder
- Suicide attempt
- Personality change
- Dystonia
- Dyskinesia
- Sedation
- Blood glucose increased
- Antipsychotic drug level below therapeutic
Drug interactions
- High Risk QT Prolonging Agents
Key clinical trials
- Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
- Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease (NA)
- Assessment of SSD in Outpatients Using SSS-CN
- Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia (NA)
- Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia (NA)
- A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy (PHASE4)
- Bioequivalence Study to Compare Two Formulations of Deanxit® (PHASE1)
- The Role of Neuromodulators in Refractory Functional Dyspepsia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluanxol CI brief — competitive landscape report
- Fluanxol updates RSS · CI watch RSS